The AKT2/SIRT5/TFEB pathway as a potential therapeutic target in atrophic AMD
S. Ghosh, R. Sharma, S. Bammidi, V. Koontz, M. Nemani, M. Yazdankhah, K. M. Kedziora, C. T. Wallace, C. Yu-Wei, J. Franks, D. Bose, D. Rajasundaram, S. Hose, J.-A. Sahel, R. Puertollano, , D. Sinha
This study identifies the AKT2/SIRT5/TFEB pathway as a therapeutic target for atrophic AMD by showing its role in lysosomal dysfunction and drusen formation in RPE cells.
bioRxiv · Aug 8, 2023 · PreprintCell Biology